Trials / Completed
CompletedNCT03458260
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
A Multicentre, Phase II, Open Label, Single Arm Study of Pixantrone in Patients With CD20-positive Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated With Rituximab, Ifosfamide and Etoposide.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- The Lymphoma Academic Research Organisation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.
Detailed description
This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pixantrone | 6 cycles - dose = 80mg/m² |
| OTHER | Ifosfamide | 6 cycles - 1500 mg/m2 |
| OTHER | Etoposide | 6 cycles - 150 mg/m2 |
| OTHER | Rituximab | 6 cycles - 375 mg/m2 |
| PROCEDURE | Transplant | after 2 or 6 cycles |
Timeline
- Start date
- 2018-12-26
- Primary completion
- 2024-12-24
- Completion
- 2024-12-24
- First posted
- 2018-03-08
- Last updated
- 2026-03-10
Locations
22 sites across 2 countries: Belgium, France
Source: ClinicalTrials.gov record NCT03458260. Inclusion in this directory is not an endorsement.